MATINAS BIOPHARMA HOLDINGS I (MTNB)
US5768101058 - Common Stock
MTNB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. MTNB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MTNB is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MTNB has reported negative net income.
In the past year MTNB has reported a negative cash flow from operations.
MTNB had negative earnings in each of the past 5 years.
MTNB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
MTNB's Return On Assets of -94.04% is on the low side compared to the rest of the industry. MTNB is outperformed by 74.69% of its industry peers.
MTNB has a Return On Equity of -119.94%. This is comparable to the rest of the industry: MTNB outperforms 40.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -94.04% | ||
| ROE | -119.94% | ||
| ROIC | N/A |
ROA(3y)-58.95%
ROA(5y)-51.01%
ROE(3y)-73.87%
ROE(5y)-62.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MTNB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MTNB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MTNB has about the same amount of shares outstanding.
MTNB has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, MTNB has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -13.03, we must say that MTNB is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -13.03, MTNB is not doing good in the industry: 79.68% of the companies in the same industry are doing better.
MTNB has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
MTNB has a Debt to Equity ratio (0.00) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.03 |
ROIC/WACCN/A
WACC10.4%
2.3 Liquidity
A Current Ratio of 6.39 indicates that MTNB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.39, MTNB is in the better half of the industry, outperforming 65.42% of the companies in the same industry.
A Quick Ratio of 6.39 indicates that MTNB has no problem at all paying its short term obligations.
MTNB has a better Quick ratio (6.39) than 65.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.39 | ||
| Quick Ratio | 6.39 |
3. Growth
3.1 Past
MTNB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.09%, which is quite good.
MTNB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
MTNB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.71% yearly.
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-100%
Revenue growth 3Y90.58%
Revenue growth 5Y55.71%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, MTNB will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.38% on average per year.
The Revenue is expected to grow by 155.73% on average over the next years. This is a very strong growth
EPS Next Y16.55%
EPS Next 2Y1.31%
EPS Next 3Y2.37%
EPS Next 5Y15.38%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y155.73%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MTNB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTNB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.31%
EPS Next 3Y2.37%
5. Dividend
5.1 Amount
MTNB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MATINAS BIOPHARMA HOLDINGS I
NYSEARCA:MTNB (11/21/2024, 8:04:00 PM)
After market: 0.56 -0.02 (-3.43%)0.5799
+0.04 (+7.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.91M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -94.04% | ||
| ROE | -119.94% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.39 | ||
| Quick Ratio | 6.39 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y16.55%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3Y90.58%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y